Logo image of SXTP

60 DEGREES PHARMA INC (SXTP) Stock Fundamental Analysis

NASDAQ:SXTP - Nasdaq - US83006G4010 - Common Stock - Currency: USD

1.32  +0.01 (+0.76%)

After market: 1.32 0 (0%)

Fundamental Rating

2

Overall SXTP gets a fundamental rating of 2 out of 10. We evaluated SXTP against 193 industry peers in the Pharmaceuticals industry. SXTP has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, SXTP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SXTP had negative earnings in the past year.
SXTP had a negative operating cash flow in the past year.
In the past 5 years SXTP always reported negative net income.
SXTP had a negative operating cash flow in each of the past 5 years.
SXTP Yearly Net Income VS EBIT VS OCF VS FCFSXTP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

SXTP's Return On Assets of -179.62% is on the low side compared to the rest of the industry. SXTP is outperformed by 88.08% of its industry peers.
With a Return On Equity value of -261.25%, SXTP is not doing good in the industry: 72.54% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -179.62%
ROE -261.25%
ROIC N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SXTP Yearly ROA, ROE, ROICSXTP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

The Gross Margin of SXTP (50.40%) is better than 63.21% of its industry peers.
In the last couple of years the Gross Margin of SXTP has declined.
The Profit Margin and Operating Margin are not available for SXTP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
SXTP Yearly Profit, Operating, Gross MarginsSXTP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

3

2. Health

2.1 Basic Checks

SXTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SXTP has been increased compared to 1 year ago.
The debt/assets ratio for SXTP is higher compared to a year ago.
SXTP Yearly Shares OutstandingSXTP Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
SXTP Yearly Total Debt VS Total AssetsSXTP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -13.35, we must say that SXTP is in the distress zone and has some risk of bankruptcy.
SXTP has a worse Altman-Z score (-13.35) than 73.58% of its industry peers.
SXTP has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
SXTP has a Debt to Equity ratio (0.04) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -13.35
ROIC/WACCN/A
WACC10.05%
SXTP Yearly LT Debt VS Equity VS FCFSXTP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

SXTP has a Current Ratio of 3.13. This indicates that SXTP is financially healthy and has no problem in meeting its short term obligations.
SXTP has a Current ratio (3.13) which is comparable to the rest of the industry.
SXTP has a Quick Ratio of 2.71. This indicates that SXTP is financially healthy and has no problem in meeting its short term obligations.
SXTP has a Quick ratio of 2.71. This is comparable to the rest of the industry: SXTP outperforms 53.89% of its industry peers.
Industry RankSector Rank
Current Ratio 3.13
Quick Ratio 2.71
SXTP Yearly Current Assets VS Current LiabilitesSXTP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for SXTP have decreased strongly by -194.32% in the last year.
SXTP shows a strong growth in Revenue. In the last year, the Revenue has grown by 109.23%.
SXTP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -52.49% yearly.
EPS 1Y (TTM)-194.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-186.67%
Revenue 1Y (TTM)109.23%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%11.58%

3.2 Future

SXTP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.73% yearly.
SXTP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 82.46% yearly.
EPS Next Y94.26%
EPS Next 2Y38.52%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue Next Year94.66%
Revenue Next 2Y95.15%
Revenue Next 3Y82.46%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SXTP Yearly Revenue VS EstimatesSXTP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
SXTP Yearly EPS VS EstimatesSXTP Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SXTP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SXTP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SXTP Price Earnings VS Forward Price EarningsSXTP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SXTP Per share dataSXTP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

A more expensive valuation may be justified as SXTP's earnings are expected to grow with 25.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.52%
EPS Next 3Y25.73%

More info and screens

0

5. Dividend

5.1 Amount

SXTP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

60 DEGREES PHARMA INC

NASDAQ:SXTP (8/15/2025, 8:00:00 PM)

After market: 1.32 0 (0%)

1.32

+0.01 (+0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)N/A N/A
Inst Owners14.46%
Inst Owner Change1.97%
Ins Owners1.22%
Ins Owner Change0.45%
Market Cap4.26M
Analysts80
Price Target7.14 (440.91%)
Short Float %14.82%
Short Ratio0.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-131.74%
Min EPS beat(2)-247.17%
Max EPS beat(2)-16.31%
EPS beat(4)0
Avg EPS beat(4)-85.29%
Min EPS beat(4)-247.17%
Max EPS beat(4)-16.31%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-16.41%
Min Revenue beat(2)-29.6%
Max Revenue beat(2)-3.22%
Revenue beat(4)0
Avg Revenue beat(4)-30.05%
Min Revenue beat(4)-45.31%
Max Revenue beat(4)-3.22%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)20.69%
PT rev (3m)20.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.04%
EPS NY rev (1m)0%
EPS NY rev (3m)42.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.39
P/FCF N/A
P/OCF N/A
P/B 1.04
P/tB 1.08
EV/EBITDA N/A
EPS(TTM)-41.56
EYN/A
EPS(NY)-3.11
Fwd EYN/A
FCF(TTM)-1.94
FCFYN/A
OCF(TTM)-1.89
OCFYN/A
SpS0.25
BVpS1.27
TBVpS1.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -179.62%
ROE -261.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.4%
FCFM N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
F-Score3
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 302.74%
Cap/Sales 22.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.13
Quick Ratio 2.71
Altman-Z -13.35
F-Score3
WACC10.05%
ROIC/WACCN/A
Cap/Depr(3y)258.14%
Cap/Depr(5y)228.76%
Cap/Sales(3y)28.01%
Cap/Sales(5y)17.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-194.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-186.67%
EPS Next Y94.26%
EPS Next 2Y38.52%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue 1Y (TTM)109.23%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%11.58%
Revenue Next Year94.66%
Revenue Next 2Y95.15%
Revenue Next 3Y82.46%
Revenue Next 5YN/A
EBIT growth 1Y-85.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.33%
OCF growth 3YN/A
OCF growth 5YN/A